Vertex Pharmaceuticals Bolsa (NASDAQ: VRTX)

Últimas noticias sobre Vertex Pharmaceuticals (NASDAQ:VRTX) Bolsa

Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Equities

News

Markets

ETFs

$BTC

ARKF

ARKG

ARKK

ARKW

COIN

EXAS

PLTR

PSNL

VRTX

El miércoles, Cathie Wood, a la cabeza de Ark Invest, realizó algunas operaciones significativas, siendo las más destacadas las de Coinbase Global Inc (NASDAQ:COIN) y Palantir Technologies Inc (NYSE:

Movimientos clave de Cathie Wood: ¿qué hay detrás de las últimas operaciones de Ark Invest?

BLDR

SERV

VKTX

Jim Cramer analiza VRTX, SERV, BLDR y VKTX en &#39;Mad Money&#39;. Descubre por qué algunas acciones suben mientras otras caen.

Jim Cramer analiza las mejores oportunidades de inversión en &#39;Mad Money&#39;

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals Inc

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with VRTX, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 13 uncommon options trades for Vertex Pharmaceuticals.
This isn't normal.
The overall sentiment of these big-money traders is split between 46% bullish and 46%, bearish.
Out of all of the special options we uncovered, 9 are puts, for a total amount of $531,578, and 4 are calls, for a total amount of $125,460.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $415.0 and $680.0 for Vertex Pharmaceuticals, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Vertex Pharmaceuticals stands at 665.64, with a total volume reaching 1,785.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Vertex Pharmaceuticals, situated within the strike price corridor from $415.0 to $680.0, throughout the last 30 days.
<h3>Vertex Pharmaceuticals 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734553827_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$16.2</td>
<td>$14.7</td>
<td>$16.2</td>
<td>$470.00</td>
<td>$111.7K</td>
<td>2.0K</td>
<td align="right">425</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$16.1</td>
<td>$15.1</td>
<td>$16.1</td>
<td>$470.00</td>
<td>$111.0K</td>
<td>2.0K</td>
<td align="right">356</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$23.1</td>
<td>$22.1</td>
<td>$22.1</td>
<td>$460.00</td>
<td>$81.7K</td>
<td>1.6K</td>
<td align="right">53</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/27/24</td>
<td>$25.6</td>
<td>$19.0</td>
<td>$27.0</td>
<td>$462.50</td>
<td>$53.9K</td>
<td>0</td>
<td align="right">20</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$18.0</td>
<td>$17.1</td>
<td>$18.0</td>
<td>$470.00</td>
<td>$45.0K</td>
<td>2.0K</td>
<td align="right">667</td>
</tr>
</tbody>
</table>

<h3>About Vertex Pharmaceuticals</h3>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Following our analysis of the options activities associated with Vertex Pharmaceuticals, we pivot to a closer look at the company's own performance.
<h3>Where Is Vertex Pharmaceuticals Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 891,270, the VRTX's price is down by -3.75%, now at $451.64. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 47 days.</li>
</ul>
<h3>What The Experts Say On Vertex Pharmaceuticals</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $522.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Stifel has decided to maintain their Hold rating on Vertex Pharmaceuticals, which currently sits at a price target of $494. 
&#x2A; Showing optimism, an analyst from Jefferies upgrades its rating to Buy with a revised price target of $550. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Vertex Pharmaceuticals options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Check Out What Whales Are Doing With VRTX

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Stifel raised the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from $490 to $494. Stifel analyst Paul Matteis maintained a Hold rating. Vertex Pharmaceuticals shares closed at $463.73 on Friday. See how other analysts view this stock.</li>
<li>Jefferies raised the price target for Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) from $63 to $70. Jefferies analyst Akash Tewari upgraded the stock from Hold to Buy. Bristol-Myers Squibb shares closed at $55.78 on Friday. <a href="https://www.benzinga.com/quote/BMY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Oppenheimer boosted the price target for Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) from $825 to $1,065. Oppenheimer analyst Jason Helfstein maintained an Outperform rating. Netflix shares closed at $918.87 on Friday. <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley cut MKS Instruments, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) price target from $155 to $150. Morgan Stanley analyst Joseph Moore maintained an Overweight rating. MKS Instruments shares settled at $112.55 on Friday. <a href="https://www.benzinga.com/quote/MKSI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital raised RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) price target from $320 to $450. Loop Capital analyst Anthony Chukumba maintained a Hold rating. Walmart shares closed at $446.04 on Friday. <a href="https://www.benzinga.com/quote/RH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank cut NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) price target from $92 to $82. Deutsche Bank analyst Krisztina Katai maintained a Buy rating. NIKE shares closed at $77.25 on Friday.  <a href="https://www.benzinga.com/quote/NKE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt raised The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) price target from $122 to $135. Rosenblatt analyst Barton Crockett maintained a Buy rating. Disney shares closed at $113.34 on Friday. See how other analysts view this stock.</li>
<li>Mizuho cut the price target for Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) from $137 to $134. Mizuho analyst Nitin Kumar maintained a Neutral rating. Exxon Mobil shares settled at $110.84 on Friday. <a href="https://www.benzinga.com/quote/XOM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho raised CNX Resources Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNX#NYSE">CNX</a>) price target from $33 to $38. Mizuho analyst Nitin Kumar downgraded the stock from Neutral to Underperform. CNX Resources shares closed at $37.79 on Friday. <a href="https://www.benzinga.com/quote/CNX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush raised Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) price target from $400 to $515. Wedbush analyst Daniel Ives maintained an Outperform rating. Tesla shares closed at $436.23 on Friday. <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying TSLA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="483" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16083522/image-126-1024x483.png" alt="" class="wp-image-693891" style="width:557px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16083522/image-126-1024x483.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16083522/image-126-300x142.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16083522/image-126-768x362.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16083522/image-126.png 1176w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42482639/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-with-over-6-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks With Over 6% Dividend Yields</a></li>
</ul>

Price Target

Pre-Market Outlook

Analyst Ratings

Trading Ideas

MKSI

NFLX

TSLA

Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday

Stifel analyst Paul Matteis maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Hold and raises the price target from $490 to $494.

Stifel Maintains Hold on Vertex Pharmaceuticals, Raises Price Target to $494

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) has outperformed the market over the past 20 years by 12.15% on an annualized basis producing an average annual return of 20.56%. Currently, Vertex Pharmaceuticals has a market capitalization of $118.76 billion. 
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 20 years ago, it would be worth $4,227.04 today based on a price of $461.17 for VRTX at the time of writing.
<h3>Vertex Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734104714_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>XRAY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$20.00</td>
<td>$40.5K</td>
<td>3.2K</td>
<td>2.1K</td>
</tr>
<tr>
<td>RXRX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$9.00</td>
<td>$30.0K</td>
<td>8.4K</td>
<td>1.7K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$50.00</td>
<td>$86.8K</td>
<td>9.6K</td>
<td>1.2K</td>
</tr>
<tr>
<td>LFST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$7.00</td>
<td>$35.0K</td>
<td>1.8K</td>
<td>1.0K</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$42.00</td>
<td>$33.0K</td>
<td>536</td>
<td>281</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$95.00</td>
<td>$44.7K</td>
<td>439</td>
<td>161</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$145.00</td>
<td>$26.1K</td>
<td>2.0K</td>
<td>95</td>
</tr>
<tr>
<td>ELV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$470.00</td>
<td>$33.2K</td>
<td>22</td>
<td>20</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$65.00</td>
<td>$29.1K</td>
<td>278</td>
<td>11</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$470.00</td>
<td>$29.0K</td>
<td>1</td>
<td>10</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For XRAY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>), we notice a call option trade that happens to be neutral, expiring in 128 day(s) on April 17, 2025. This event was a transfer of 225 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $40.5K, with a price of $180.0 per contract. There were 3202 open contracts at this strike prior to today, and today 2122 contract(s) were bought and sold. 
• Regarding RXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), we observe a call option sweep with bullish sentiment. It expires in 38 day(s) on January 17, 2025. Parties traded 400 contract(s) at a $9.00 strike. This particular call needed to be split into 17 different trades to become filled. The total cost received by the writing party (or parties) was $30.0K, with a price of $75.0 per contract. There were 8401 open contracts at this strike prior to today, and today 1738 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a put option sweep with bearish sentiment. It expires in 101 day(s) on March 21, 2025. Parties traded 482 contract(s) at a $50.00 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $86.8K, with a price of $180.0 per contract. There were 9650 open contracts at this strike prior to today, and today 1214 contract(s) were bought and sold. 
• Regarding LFST (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFST#NASDAQ">LFST</a>), we observe a call option trade with bullish sentiment. It expires in 38 day(s) on January 17, 2025. Parties traded 500 contract(s) at a $7.00 strike. The total cost received by the writing party (or parties) was $35.0K, with a price of $70.0 per contract. There were 1847 open contracts at this strike prior to today, and today 1000 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option sweep that happens to be bearish, expiring in 38 day(s) on January 17, 2025. This event was a transfer of 314 contract(s) at a $42.00 strike. This particular call needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $33.0K, with a price of $105.0 per contract. There were 536 open contracts at this strike prior to today, and today 281 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a call option trade that happens to be bearish, expiring in 101 day(s) on March 21, 2025. This event was a transfer of 50 contract(s) at a $95.00 strike. The total cost received by the writing party (or parties) was $44.7K, with a price of $895.0 per contract. There were 439 open contracts at this strike prior to today, and today 161 contract(s) were bought and sold. 
• Regarding JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we observe a put option sweep with bearish sentiment. It expires in 101 day(s) on March 21, 2025. Parties traded 67 contract(s) at a $145.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $26.1K, with a price of $390.0 per contract. There were 2061 open contracts at this strike prior to today, and today 95 contract(s) were bought and sold. 
• For ELV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), we notice a call option trade that happens to be neutral, expiring in 283 day(s) on September 19, 2025. This event was a transfer of 20 contract(s) at a $470.00 strike. The total cost received by the writing party (or parties) was $33.2K, with a price of $1660.0 per contract. There were 22 open contracts at this strike prior to today, and today 20 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a put option trade that happens to be neutral, expiring in 402 day(s) on January 16, 2026. This event was a transfer of 11 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $29.1K, with a price of $2654.0 per contract. There were 278 open contracts at this strike prior to today, and today 11 contract(s) were bought and sold. 
• For VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we notice a put option trade that happens to be bullish, expiring in 45 day(s) on January 24, 2025. This event was a transfer of 10 contract(s) at a $470.00 strike. The total cost received by the writing party (or parties) was $29.0K, with a price of $2900.0 per contract. There were 1 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LFST

RXRX

XRAY

10 Health Care Stocks With Whale Alerts In Today's Session

Jefferies has upgraded Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), citing the company&#8217;s robust cystic fibrosis base business and the additional upside from the new LNP/ mRNA therapy (around $1 billion opportunity) and &#8220;triple pill&#8221; regimens.
The company&#8217;s pipeline can potentially exceed expectations if the data is positive. The analyst views the risk/reward balance as mostly neutral for 2024. The pain program stands out as a potential blockbuster, especially with the upcoming launch for acute pain and chronic LSR data expected in 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42324351/fda-approved-sickle-cell-therapies-from-bluebird-bio-and-vertex-join-medicaid-innovation-program" rel="noreferrer noopener">FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program</a>
Jefferies upgraded Vertex to Buy from Hold following improved fundamentals and a growing pipeline worth $5 billion-7 billion, which includes treatments for chronic pain and APOL1 kidney disease. The analyst increased the <a target="_blank" href="https://www.benzinga.com/quote/VRTX/analyst-ratings" rel="noreferrer noopener">price target from $500 to $550</a>.
A recent meeting with management indicates that their Nav 1.8 pain treatment is improving and could be combined with next-gen 1.7 and 1.8 dual mechanisms, similar to their CF combination treatments, potentially creating a $5 billion+ business.
The Phase 3 AMKD kidney trial is also progressing well, with promising results expected to lead to a $2 billion business. Investors should consider Vertex to be a valuable asset in the current market.
Due to its solid fundamentals and expanding pipeline, Vertex is a strong growth stock that should remain a favorite among general investors and long-term holders.
It&#8217;s a rare growth opportunity in the large biopharma sector, with no significant data risks expected in 2025 and no concerns over obesity-related issues.
In the near term, the analyst anticipates positive Phase 2 LSR pain data, a successful launch of Vanza for cystic fibrosis in 2025, and continued strong financial performance.
Price Action: VRTX stock is up 2.16% at $472.06 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/12/42395322/warner-bros-discovery-stock-soars-after-multi-year-deal-with-comcast-comcast-shares-slide-on-subscriber-loss-estimates" target="_blank" rel="noreferrer noopener">Warner Bros Discovery Stock Soars After Multi-Year Deal with Comcast; Comcast Shares Slide On Subscriber Loss Estimates</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Biotech

Large Cap

Upgrades

Health Care

General

Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock

In the last three months, 19 analysts have published ratings on Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $499.21, a high estimate of $600.00, and a low estimate of $408.00. This current average has increased by 3.38% from the previous average price target of $482.88. 
<img src="https://www.benzinga.com/files/images/story/2024/1733752855_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Vertex Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Yee</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$550.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$575.00</td>
<td>-</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Sell</td>
<td>$408.00</td>
<td>$361.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$486.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$586.00</td>
<td>$562.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$451.00</td>
<td>$437.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$503.00</td>
<td>$510.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$476.00</td>
<td>$473.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$540.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$600.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$562.00</td>
<td>$477.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$480.00</td>
<td>-</td>
</tr>
<tr>
<td>Ying Huang</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$541.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$437.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$425.00</td>
<td>$431.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$474.00</td>
<td>$462.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$431.00</td>
<td>$431.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Vertex Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Vertex Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Vertex Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Vertex Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/VRTX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Vertex Pharmaceuticals analyst ratings.</a>
<h2>Discovering Vertex Pharmaceuticals: A Closer Look</h2>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
<h3>A Deep Dive into Vertex Pharmaceuticals's Financials</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Vertex Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 11.61%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 37.71%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Vertex Pharmaceuticals's ROE stands out, surpassing industry averages. With an impressive ROE of 6.88%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Vertex Pharmaceuticals's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.93% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Vertex Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.11.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 19 Analysts

Jefferies analyst Michael Yee upgrades Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from Hold to Buy and raises the price target from $500 to $550.

Jefferies Upgrades Vertex Pharmaceuticals to Buy, Raises Price Target to $550

<ul>
<li>Data from long-term follow-up of patients in clinical trials further demonstrate durability of the transformative benefits of CASGEVY&#x2122; -</li>
<li>- Safety profile consistent with busulfan conditioning and autologous hematopoietic stem cell transplant -</li>
<li>- Vertex provides update on progress in bringing CASGEVY to patients -</li>
</ul>

Reported Sunday, Vertex Highlights Long-Term Benefits Of CASGEVY For Sickle Cell Disease And Beta Thalassemia At ASH 2024

The Biden-Harris administration has announced an initiative to improve access to gene therapies for <a href="https://www.benzinga.com/topic/sickle-cell-disease">sickle cell disease</a> under the Cell and Gene Therapy Access Model.
This voluntary model, developed by the Center for Medicare and Medicaid Innovation, seeks to enhance access to these therapies, improve patient outcomes, and reduce healthcare costs by tying payments to treatment efficacy for Medicaid recipients.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42243241/fda-probes-potential-life-threatening-blood-cancer-risks-linked-to-bluebird-bios-skysona-gene-therapy" rel="noreferrer noopener">FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio&#8217;s Skysona Gene Therapy</a>
Two drug manufacturers, Bluebird Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) and Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), have agreed to participate in the model with their FDA-approved therapies, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42016766/jp-morgan-downgrades-gene-therapy-focused-bluebird-bio-cites-limited-funding-options" rel="noreferrer noopener">Lyfgenia</a> and <a target="_blank" href="https://www.benzinga.com/news/24/01/36657324/gene-therapy-for-beta-thalassemia-crispr-therapeuticsvertexs-casgevy-secures-fda-nod-ahead-of-schedu" rel="noreferrer noopener">Casgevy</a>.
CMS is working to <a target="_blank" href="https://www.cms.gov/newsroom/press-releases/biden-harris-administration-takes-next-steps-increase-access-sickle-cell-disease-treatments" rel="noreferrer noopener">engage</a> states and U.S. territories enrolled in the Medicaid Drug Rebate Program, providing technical support and data infrastructure for implementation.
States may apply to participate starting this month, with applications accepted until Feb. 28, 2025.
Over 100,000 individuals in the U.S. live with sickle cell disease, more than half of whom rely on Medicaid. The disease significantly reduces life expectancy and imposes an annual economic burden of nearly $3 billion in healthcare costs.
The Food and Drug Administration (FDA) approved Lyfgenia and Casgevy in December 2023 as gene therapies targeting <a href="https://www.benzinga.com/general/biotech/23/12/36156713/fda-approves-first-gene-editing-cell-therapy-for-sickle-cell-disease-an-inherited-blood-disorder" target="_blank" rel="noreferrer noopener">sickle cell disease</a>.
Launching in January 2025, the model allows states to join until January 2026. States can also apply for optional funding to support implementation.
This initiative aligns with President Biden's 2022 Executive Order to expand access to novel therapies and reduce prescription drug costs. Future expansions of the model may include other cell and gene therapies.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42321484/fords-mustang-mach-e-sales-skyrocket-383-in-november-amid-growing-ev-momentum" target="_blank" rel="noreferrer noopener">Ford&#8217;s Mustang Mach-E Sales Skyrocket 38.3% In November Amid Growing EV Momentum</a></li>
</ul>
Image: Shutterstock

BLUE

FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RXRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$9.00</td>
<td>$107.2K</td>
<td>9.1K</td>
<td>2.4K</td>
</tr>
<tr>
<td>SRRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$40.00</td>
<td>$29.6K</td>
<td>4.6K</td>
<td>1.1K</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$575.00</td>
<td>$36.0K</td>
<td>57</td>
<td>518</td>
</tr>
<tr>
<td>PACB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$5.00</td>
<td>$25.2K</td>
<td>668</td>
<td>405</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$33.00</td>
<td>$31.1K</td>
<td>630</td>
<td>367</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/13/24</td>
<td>$112.00</td>
<td>$68.8K</td>
<td>260</td>
<td>188</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$960.00</td>
<td>$66.1K</td>
<td>1.8K</td>
<td>177</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$32.50</td>
<td>$37.7K</td>
<td>4.0K</td>
<td>51</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$500.00</td>
<td>$28.0K</td>
<td>103</td>
<td>35</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$60.00</td>
<td>$68.4K</td>
<td>292</td>
<td>12</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For RXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), we notice a call option trade that happens to be bearish, expiring in 44 day(s) on January 17, 2025. This event was a transfer of 1650 contract(s) at a $9.00 strike. The total cost received by the writing party (or parties) was $107.2K, with a price of $65.0 per contract. There were 9105 open contracts at this strike prior to today, and today 2455 contract(s) were bought and sold. 
• For SRRK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>), we notice a call option sweep that happens to be bullish, expiring in 44 day(s) on January 17, 2025. This event was a transfer of 76 contract(s) at a $40.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $29.6K, with a price of $390.0 per contract. There were 4683 open contracts at this strike prior to today, and today 1199 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option trade with bearish sentiment. It expires in 16 day(s) on December 20, 2024. Parties traded 200 contract(s) at a $575.00 strike. The total cost received by the writing party (or parties) was $36.0K, with a price of $180.0 per contract. There were 57 open contracts at this strike prior to today, and today 518 contract(s) were bought and sold. 
• For PACB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>), we notice a call option trade that happens to be bullish, expiring in 772 day(s) on January 15, 2027. This event was a transfer of 389 contract(s) at a $5.00 strike. The total cost received by the writing party (or parties) was $25.2K, with a price of $65.0 per contract. There were 668 open contracts at this strike prior to today, and today 405 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option trade that happens to be bearish, expiring in 79 day(s) on February 21, 2025. This event was a transfer of 62 contract(s) at a $33.00 strike. The total cost received by the writing party (or parties) was $31.1K, with a price of $502.0 per contract. There were 630 open contracts at this strike prior to today, and today 367 contract(s) were bought and sold. 
• For NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we notice a call option sweep that happens to be bullish, expiring in 9 day(s) on December 13, 2024. This event was a transfer of 166 contract(s) at a $112.00 strike. This particular call needed to be split into 37 different trades to become filled. The total cost received by the writing party (or parties) was $68.8K, with a price of $415.0 per contract. There were 260 open contracts at this strike prior to today, and today 188 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option trade with bearish sentiment. It expires in 107 day(s) on March 21, 2025. Parties traded 29 contract(s) at a $960.00 strike. The total cost received by the writing party (or parties) was $66.1K, with a price of $2280.0 per contract. There were 1883 open contracts at this strike prior to today, and today 177 contract(s) were bought and sold. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a put option sweep that happens to be bearish, expiring in 107 day(s) on March 21, 2025. This event was a transfer of 51 contract(s) at a $32.50 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $37.7K, with a price of $740.0 per contract. There were 4013 open contracts at this strike prior to today, and today 51 contract(s) were bought and sold. 
• Regarding VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we observe a call option trade with bearish sentiment. It expires in 134 day(s) on April 17, 2025. Parties traded 10 contract(s) at a $500.00 strike. The total cost received by the writing party (or parties) was $28.0K, with a price of $2800.0 per contract. There were 103 open contracts at this strike prior to today, and today 35 contract(s) were bought and sold. 
• For SAVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>), we notice a put option trade that happens to be bearish, expiring in 16 day(s) on December 20, 2024. This event was a transfer of 12 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $68.4K, with a price of $5704.0 per contract. There were 292 open contracts at this strike prior to today, and today 12 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PACB

SAVA

SRRK

10 Health Care Stocks Whale Activity In Today's Session

Vertex Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NYSE">VRTX</a>) short percent of float has risen 5.42% since its last report. The company recently reported that it has 4.50 million shares sold short, which is 1.75% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.52 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Vertex Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732560311_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Vertex Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Vertex Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 5.14%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Vertex Pharmaceuticals's Recent Short Interest

Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals.
Looking at options history for Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 50% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $266,785 and 3, calls, for a total amount of $162,840.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $420.0 to $550.0 for Vertex Pharmaceuticals during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Vertex Pharmaceuticals's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Vertex Pharmaceuticals's whale trades within a strike price range from $420.0 to $550.0 in the last 30 days. 
<h3>Vertex Pharmaceuticals Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731961818_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$15.8</td>
<td>$14.6</td>
<td>$15.0</td>
<td>$450.00</td>
<td>$99.0K</td>
<td align="right">500</td>
<td align="right">66</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$46.8</td>
<td>$41.8</td>
<td>$44.0</td>
<td>$440.00</td>
<td>$88.0K</td>
<td align="right">439</td>
<td align="right">20</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$15.3</td>
<td>$13.6</td>
<td>$15.0</td>
<td>$450.00</td>
<td>$51.0K</td>
<td align="right">500</td>
<td align="right">100</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$50.9</td>
<td>$44.8</td>
<td>$46.02</td>
<td>$420.00</td>
<td>$46.0K</td>
<td align="right">0</td>
<td align="right">10</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.95</td>
<td>$2.65</td>
<td>$2.65</td>
<td>$550.00</td>
<td>$40.2K</td>
<td align="right">69</td>
<td align="right">152</td>
</tr>
</tbody>
</table>

<h3>About Vertex Pharmaceuticals</h3>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Following our analysis of the options activities associated with Vertex Pharmaceuticals, we pivot to a closer look at the company's own performance.
<h3>Vertex Pharmaceuticals's Current Market Status</h3>
<ul>
<li>With a volume of 565,702, the price of VRTX is up 0.06% at $466.0. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 77 days.</li>
</ul>
<h3>Expert Opinions on Vertex Pharmaceuticals</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $492.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Perform rating for Vertex Pharmaceuticals, targeting a price of $486. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Vertex Pharmaceuticals with a target price of $503. 
&#x2A; Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for Vertex Pharmaceuticals, targeting a price of $540. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $480. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on Vertex Pharmaceuticals with a target price of $451. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Vertex Pharmaceuticals, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics

WIIM

Shares of pharmaceutical companies are trading lower After President-elect Trump nominated Robert F. Kennedy Jr. to lead the HHS.

<a href="https://www.mckesson.com/about-mckesson/newsroom/press-releases/2024/inspirogene-by-mckesson-partners-with-vertex-to-expand-distribution-options-for-casgevy/" title="https://www.mckesson.com/about-mckesson/newsroom/press-releases/2024/inspirogene-by-mckesson-partners-with-vertex-to-expand-distribution-options-for-casgevy/">https://www.mckesson.com/about-mckesson/newsroom/press-releases/2024/inspirogene-by-mckesson-partners-with-vertex-to-expand-distribution-options-for-casgevy/</a>

InspiroGene by McKesson Partners With Vertex To Expand Distribution Of CASGEVY, The First FDA-Approved CRISPR Gene-Editing Therapy For Sickle Cell Disease And β-Thalassemia

Citigroup analyst Geoff Meacham initiates coverage on Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Buy rating and announces Price Target of $575.

Initiation

Citigroup Initiates Coverage On Vertex Pharmaceuticals with Buy Rating, Announces Price Target of $575

Canaccord Genuity analyst Whitney Ijem maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sell and raises the price target from $361 to $408.

Canaccord Genuity Maintains Sell on Vertex Pharmaceuticals, Raises Price Target to $408

Scotiabank analyst Greg Harrison maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and raises the price target from $480 to $486.

Scotiabank Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $486

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with VRTX, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 19 uncommon options trades for Vertex Pharmaceuticals.
This isn't normal.
The overall sentiment of these big-money traders is split between 47% bullish and 42%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $201,378, and 17 are calls, for a total amount of $1,435,690.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $370.0 and $700.0 for Vertex Pharmaceuticals, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Vertex Pharmaceuticals's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Vertex Pharmaceuticals's significant trades, within a strike price range of $370.0 to $700.0, over the past month.
<h3>Vertex Pharmaceuticals Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730831527_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$34.4</td>
<td>$32.5</td>
<td>$32.5</td>
<td>$490.00</td>
<td>$396.5K</td>
<td style="text-align: right;">348</td>
<td style="text-align: right;">135</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$33.5</td>
<td>$29.2</td>
<td>$31.5</td>
<td>$490.00</td>
<td>$245.7K</td>
<td style="text-align: right;">348</td>
<td style="text-align: right;">213</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$85.0</td>
<td>$81.4</td>
<td>$85.0</td>
<td>$400.00</td>
<td>$170.0K</td>
<td style="text-align: right;">79</td>
<td style="text-align: right;">20</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$10.4</td>
<td>$6.4</td>
<td>$8.87</td>
<td>$450.00</td>
<td>$169.8K</td>
<td style="text-align: right;">36</td>
<td style="text-align: right;">196</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$57.8</td>
<td>$56.1</td>
<td>$56.1</td>
<td>$480.00</td>
<td>$123.4K</td>
<td style="text-align: right;">45</td>
<td style="text-align: right;">22</td>
</tr>
</tbody>
</table>

<h3>About Vertex Pharmaceuticals</h3>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Following our analysis of the options activities associated with Vertex Pharmaceuticals, we pivot to a closer look at the company's own performance.
<h3>Vertex Pharmaceuticals's Current Market Status</h3>
<ul>
<li>Trading volume stands at 647,404, with VRTX's price up by 4.99%, positioned at $496.38.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 90 days.</li>
</ul>
<h3>Expert Opinions on Vertex Pharmaceuticals</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $500.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on Vertex Pharmaceuticals, which currently sits at a price target of $503. 
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on Vertex Pharmaceuticals, which currently sits at a price target of $540. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Vertex Pharmaceuticals with a target price of $541. 
&#x2A; An analyst from Scotiabank downgraded its action to Sector Perform with a price target of $480. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on Vertex Pharmaceuticals with a target price of $437. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Vertex Pharmaceuticals, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity

Wall Street rallied on Tuesday as improved investor sentiment aligned with millions of Americans casting their votes <a href="https://www.benzinga.com/topic/2024-election">for the 47th president.</a>
Betting markets leaned slightly toward Donald Trump, with CFTC-regulated Kalshi placing Trump's win probability at 56% compared to Kamala Harris's 44%.
National polls show a close contest, with the latest New York Times/Siena College poll indicating both candidates tied at 48% in the popular vote.
The S&amp;P 500 climbed 1.2%, while the tech-focused Nasdaq 100 surged 1.5%, marking its strongest one-day increase in nearly a month. 
All 11 sectors of the S&amp;P 500 experienced gains, with consumer discretionary stocks outperforming. Small caps also joined the rally, with the Russell 2000 index gaining 1.1%.
Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) led the S&amp;P 500, with shares soaring after the artificial intelligence company surpassed quarterly earnings estimates and provided strong guidance.
In macroeconomic news, U.S. services sector activity hit over two-year highs <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41750522/us-services-sector-gauge-rises-more-than-expected-to-over-2-year-highs-as-employm">in October, outperforming expectations</a>.
Treasury yields increased by 5 basis points, while the dollar declined for a second consecutive session.
Gold edged up 0.3%, hovering near record highs, and oil prices gained 1.2% after a 3.2% surge on Monday.
Crypto sentiment was strong as well, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) jumping 4.5% to over $70,000 and Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) spiking 12%.
Read also: <a href="https://www.benzinga.com/markets/24/11/41741466/if-trump-and-republicans-sweep-dollar-may-climb-7-but-harris-win-could-bring-5-drop-says-jpmorgan">If Trump And Republicans Sweep, Dollar May Climb 7% — But Harris Win Could Bring 5% Drop, Says JPMorgan</a>
<h3 class="wp-block-heading">Tuesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,259.62</td>
<td>1.5%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,779.38</td>
<td>1.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,244.40</td>
<td>1.1%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,191.93</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:30 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent110424&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 1.1% to $575.87.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 0.9% to $421.79.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) soared 1.4% to $492.61.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 1.1% to $222.47.</li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, rising 1.7%. The Materials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, up 0.4%.</li>
</ul>
<h3 class="wp-block-heading">Monday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports included: 
<ul>
<li>Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), up 4.8%</li>
<li>Palantir Technologies Inc., up 22.8%</li>
<li>NXP Semiconductors NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>), down 6.8%</li>
<li>Diamondback Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>), down 1.6%</li>
<li>American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>), down 2.3%</li>
<li>Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), down 0.5%</li>
<li>Apollo Global Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>), up 6.2%</li>
<li>Emerson Electric Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>), up 6.8%, </li>
<li>Marathon Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>), up 3.9%, </li>
<li>Cummins Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>), up 8.8%, </li>
<li>Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>), 4.7%,</li>
<li>YUM! Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>), up 2.5%, </li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41746843/bond-market-fear-gauge-soars-to-1-year-high-ahead-of-us-election-results-bond-vigil">Bond Market Fear Gauge Soars To 1-Year High Ahead Of US Election Results: &#8216;Bond Vigilantes Have Been Voting Early&#8217;</a></li>
</ul>
Photo via Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Macro Economic Events

Bonds

Broad U.S. Equity ETFs

Commodities

Politics

Economics

Tech

$DOGE

SPDR Dow Jones Industrial Average ETF Trust

FANG

ILMN

NXPI

TRGP

Select Sector SPDR-Consumer Discretionary

YUMC

Wall Street Rallies On Election Day, Palantir Skyrockets, Bitcoin Tops $70,000: What's Driving Markets Tuesday?

Vertex reports positive long-term data for Casgevy

Vertex upgraded to buy by Jefferies on fundamentals, pipeline

uniQure's AMT-130: A Bold Step For Huntington's, But Not Without Hurdles

Vertex Pharmaceuticals: Progress Check Suggests Stock Remains A Solid Buy

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The company's sha...

TD Cowen Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)

The biotech sector's AI-driven advancements, personalized medicine demand, and streamlined regulations fuel significant market growth. Hence, investors should consider robust biotech stocks such as Vertex Pharmaceuticals (VRTX), Amgen (AMGN), and Gilead Sciences (GILD). Read on... The biotech sector is poised for a significant boom in 2025, driven by innovative adaptive trial designs that cut time and costs while enhancing drug efficacy predictions. This favorable landscape presents an opportunity for investors to explore fundamentally strong biotech stocks with promising pipelines: Vertex Pharmaceuticals Incorporated (<a href="https://stocknews.com/stock/VRTX/">VRTX</a>), Amgen Inc. (<a href="https://stocknews.com/stock/AMGN/">AMGN</a>), and Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>).
The biotech sector is revolutionizing healthcare by targeting new and rare diseases with cutting-edge vaccines and therapies, driven by the rising demand for personalized medicine. Regulatory agencies like the FDA and EMA are streamlining processes to match technological advancements, propelling the global biotechnology market toward a projected $3.88 trillion by 2030, with an impressive <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">CAGR of 14%</a>.
Notably, AI and machine learning are transforming drug discovery by optimizing molecule screening and improving clinical outcome analysis. Beyond oncology and neurology, AI is driving advancements across diverse therapeutic areas. Deloitte estimates that biopharma companies investing in AI over the next five years could see up to an <a href="https://www2.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2025-life-sciences-executive-outlook.html">11% increase</a> in value relative to revenue across various functional areas.
Furthermore, investors' interest in biotech stocks is evident from the SPDR S&amp;P Biotech ETF's (<a href="https://stocknews.com/stock/XBI/">XBI</a>) 20.6% returns over the past year. Considering these conducive trends, let's analyze the fundamental aspects of the three <a href="https://stocknews.com/category/biotech/">Biotech</a> picks, beginning with the third choice.
Stock #3: Vertex Pharmaceuticals Incorporated (<a href="https://stocknews.com/stock/VRTX/">VRTX</a>)
VRTX is a biotechnology company that develops and commercializes therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO.
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/e/ebit.asp">EBIT</a> margin, VRTX's 39.89% is considerably higher than the 2.49% industry average. Likewise, its 28.83% trailing-12-month levered FCF margin is significantly higher than the 2.32% industry average. Furthermore, its 0.48x trailing-12-month asset turnover ratio is 17.3% higher than the 0.41x industry average.
VRTX's net revenues for the third quarter, which ended on September 30, 2024, increased 11.6% year-over-year to $2.77 billion. Its non-GAAP net income stood at $1.05 billion, or $4.01 per share, up 7.5% and 7.4%, respectively, compared to the prior-year quarter. Furthermore, its non-GAAP operating income rose 11.4% year-over-year to $1.31 billion.
Street expects VRTX's revenue for the quarter ending December 31, 2024, to increase 10.5% year-over-year to $2.78 billion. Its EPS for fiscal 2025 is expected to grow considerably year-over-year to $18.79. It surpassed the Street EPS estimates in three of the trailing four quarters. Over the past year, VRTX's stock has gained 30.4% to close the last trading session at $464.50.
VRTX's positive outlook is reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. It has an overall rating of B, equating to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It has a B grade for Value, Stability, and Sentiment. Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, it is ranked #21 out of 335 stocks in the Biotech industry. Beyond what we stated above, we also have given VRTX grades for Growth, Momentum, and Quality. Get all the VRTX ratings <a href="https://stocknews.com/stock/VRTX/">here</a>.
Stock #2: Amgen Inc. (<a href="https://stocknews.com/stock/AMGN/">AMGN</a>)
AMGN discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/haematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. Its product portfolio includes Enbrel, Neulasta, Prolia, and Xgeva.
On September 24, 2024, AMGN announced that TEPEZZA (Teprotumumab) has been approved in Japan for treating active Thyroid Eye Disease (TED), making it the first and only approved treatment in the country. The approval is based on positive Phase 3 trial results, with additional trials ongoing for chronic TED patients.
AMGN's trailing-12-month gross profit margin of 60.59% is 4.1% higher than the industry average of 58.20%. Likewise, its trailing-12-month EBIT margin and levered FCF margin of 20.51% and 14.06% are 723.3% and 505.5% higher than the industry averages of 2.49% and 2.32%, respectively.
During the fiscal third quarter, which ended on September 30, 2024, AMGN's total revenues and non-GAAP operating income increased by 23.2% and 18.8% year-over-year, reaching $8.50 billion and $4.04 billion, respectively. Moreover, its non-GAAP net income grew 13.4% compared to the previous year, reaching $3.02 billion. Also, its non-GAAP net income per share grew 12.5% from the year-ago value to $5.58.
Analysts expect AMGN's revenue for the quarter ending December 31, 2024, to increase 8.1% year-over-year to $8.86 billion. Its EPS for the same quarter is expected to grow 7.1% year-over-year to $5.04. The company surpassed the Street EPS estimates in three of the trailing four quarters. Over the past year, the stock has gained marginally closing the last trading session at $274.78.
AMGN's POWR Ratings reflect its positive prospects. It has an overall B rating, equating to Buy in our proprietary rating system.
AMGN has a B grade for Growth and Quality. Within the same industry, it is ranked #17. <a href="https://stocknews.com/stock/AMGN/">Click here</a> for the additional POWR Ratings of AMGN (Value, Momentum, Stability, and Sentiment).
Stock #1: Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>)
GILD discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
On December 3, 2024, GILD and Tubulis announced an exclusive option and license agreement to develop an antibody-drug conjugate (ADC) for a solid tumor target. The collaboration leverages Tubulis' advanced ADC platforms and GILD's oncology expertise to address challenges like durability and off-target toxicity.
On September 10, 2024, GILD and Genesis Therapeutics announced a collaboration to use Genesis' GEMS AI platform to discover and optimize small molecule therapies for selected targets. GILD gains exclusive rights to develop and commercialize the resulting compounds.
In terms of the trailing-12-month EBITDA margin, GILD's 49.29% is 763.7% higher than the 5.71% industry average. Likewise, its 77.80% trailing-12-month gross profit margin is 33.7% higher than the 58.20% industry average. Its 0.48x trailing-12-month asset turnover ratio is 17.5% higher than the 0.41x industry average.
In the fiscal third quarter, which ended on September 30, 2024, GILD's total revenues increased 7% year-over-year to $7.55 billion. The company's non-GAAP operating income was $3.26 billion, up 1.1% from the previous year's quarter. Additionally, its non-GAAP net income attributable to GILD stood at $2.53 billion, or $2.02 per share.
For the quarter ending December 31, 2024, GILD's revenue is expected to increase marginally year-over-year to $7.15 billion. Its EPS for fiscal 2025 is expected to grow 71.4% year-over-year to $7.56. GILD surpassed the EPS estimates in three of the trailing four quarters. Over the past six months, the stock has gained 41.4% to close the last trading session at $91.77.
It's no surprise that GILD has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It is ranked first in the Biotech industry. It has an A grade for Value and a B for Growth, Sentiment, and Quality. <a href="https://stocknews.com/stock/GILD/">Click here</a> to see GILD's Momentum and Stability ratings.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
AMGN shares were trading at $273.03 per share on Thursday afternoon, down $0.38 (-0.14%). Year-to-date, AMGN has declined -2.34%, versus a 28.52% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/amgn-vrtx-gild-3-biotech-stocks-with-promising-pipelines/>3 Biotech Stocks With Promising Pipelines</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Stocks With Promising Pipelines

Stifel raised the firm's price target on Vertex Pharmaceuticals (VRTX) to $494 from $490 and keeps a Hold rating on the shares. With shares up 14% ...

Vertex Pharmaceuticals price target raised to $494 from $490 at Stifel

PepGen stock craters 35% on FDA clinical hold

PepGen stock down 22% on FDA clinical hold (update)

AMGN

CPRX

CRSP

EWTX

GILD

LZAGF

LZAGY

MSCLF

PEPG

QURE

RGNX

RHHBY

SLDB

SRPT

TRDA

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Press Releases

Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY® (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis Conference

Vertex Announces Health Canada Acceptance of New Drug Submission for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-in-Class Triple Combination Treatment for Cystic Fibrosis

Entertainment

Real Estate

The Week in Canadian Press Releases: 10 Stories You Need to See

Vertex to Announce Third Quarter 2024 Financial Results on November 4th

Vertex to Present Phase 3 Data Highlighting Suzetrigine's Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting

Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress

Vertex to Participate in Upcoming November Investor Conferences

Vertex Reports Third Quarter 2024 Financial Results

Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update

Comments

Vertex Pharmaceuticals

Noticias

Últimas noticias sobre Vertex Pharmaceuticals (NASDAQ:VRTX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL